Related Experiment Videos
[Synthesis of substituted benzeneseleninic acid and its antineoplastic activity]
Abstract:
In view of the negative relationship between selenium and cancer, we designed and synthesized eleven substituted benzeneselenic acids (IVa-k) The antineoplastic activity of the title compounds was evaluated via the tests of inhibition of acetylcholinesterase, HL-60 and K562 in vitro, and Ehrlich carcinoma in mice. The result showed that the compounds IVa and IVb had distinct antineoplastic activity. The life span increase rate of IVb on mice bearing Ehrlich carcinoma was 20.30% (20mg/kg), which was higher than the increase rate of sodium selenite (10.65%, 0.5mg/kg).
Insights
Researchers explored substituted benzeneselenic acids for cancer treatment. Compounds IVa and IVb demonstrated significant antineoplastic activity, with IVb outperforming sodium selenite in extending survival in mice with Ehrlich carcinoma.
Area of Science:
- Medicinal Chemistry
- Oncology
- Biochemistry
Context:
- The established link between selenium and cancer prevention necessitates further investigation into selenium compounds.
- Developing novel chemotherapeutic agents is crucial for improving cancer treatment outcomes.
Purpose:
- To design and synthesize novel substituted benzeneselenic acids.
- To evaluate the antineoplastic potential of these compounds against various cancer models.
Summary:
- Eleven substituted benzeneselenic acids (IVa-k) were synthesized and tested for anticancer properties.
- In vitro assays included acetylcholinesterase inhibition and activity against HL-60 and K562 cancer cell lines.
- In vivo studies using Ehrlich carcinoma in mice revealed significant antineoplastic effects for compounds IVa and IVb.
Impact:
- Compound IVb showed a 20.30% increase in lifespan in mice with Ehrlich carcinoma, exceeding the 10.65% increase observed with sodium selenite.
- These findings highlight the potential of substituted benzeneselenic acids as a new class of anticancer agents.